CO6150163A2 - Composiciones adecuadas para administracion oral que comprende un derivado de triazolo [4,5-d] pirimidina - Google Patents
Composiciones adecuadas para administracion oral que comprende un derivado de triazolo [4,5-d] pirimidinaInfo
- Publication number
- CO6150163A2 CO6150163A2 CO09017334A CO09017334A CO6150163A2 CO 6150163 A2 CO6150163 A2 CO 6150163A2 CO 09017334 A CO09017334 A CO 09017334A CO 09017334 A CO09017334 A CO 09017334A CO 6150163 A2 CO6150163 A2 CO 6150163A2
- Authority
- CO
- Colombia
- Prior art keywords
- pharmaceutical composition
- mixture
- calcium phosphate
- sodium
- weight
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2009—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Inorganic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Immunology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
1.- Una composición farmacéutica la cual comprende: {1S-[1a, 2a, 3ß(1S*,2R*) ,5ß] )-3-(7-{[2-(3,4-difluorofenil) ciclopropil]amino}-5-(propiltio)-3H-1,2,3-triazolo[4,5-d] pirimidin-3-il) -5-(2-hidroxietoxi) ciclopentano-1,2-diol; uno o más rellenos seleccionados a partir de manitol, sorbitol, dihidrato de fosfato de calcio dibásico, anhidro de fosfato de calcio dibásico y fosfato de calcio tribásico o una mezcla de los mismos; uno o más aglomerantes seleccionados entre hidroxipropilo celulosa, ácido algínico, carboximetilcelulosa sódica, copovidona y metilcelulosa o una mezcla de los mismos; uno o más desintegrantes seleccionados entre glicolato de almidón de sodio, croscarmelosa de sodio y crospovidona o una mezcla de los mismos;y uno o más lubricantes. 2.- Una composición farmacéutica tal cual se define en la reivindicación 1 en donde el relleno es una mezcla de manitol y dihidrato de fosfato de calcio dibásico. 3.- Una composición farmacéutica tal cual se define en la reivindicación 2 en donde el aglomerante es la hidroxipropilo celulosa. 4.- Una composición farmacéutica tal cual se define en la reivindicación 2 o la reivindicación 3 en donde el desintegrante es el glicolato de almidón de sodio. 5.- Una composición farmacéutica tal cual se define en cualquiera de las reivindicaciones 2 a 4 en donde el lubricante es seleccionado entre estearato de magnesio y fumarato de estearilo de sodio. 6.- Una composición farmacéutica tal cual se define en cualquiera de las reivindicaciones 2 a 5 en donde {1S-[1a, 2a, 3ß(1S*,2R*) ,5ß] )-3-(7-{[2-(3,4-difluorofenil) ciclopropil]amino}- 5-(propiltio)-3H-1,2,3-triazolo[4,5-d] pirimidin-3-il)-5-(2-hidroxietoxi) ciclopentano-1,2-diol está presente en una cantidad que oscila entre un 20 y 45% por peso. 7.- Una composición farmacéutica tal cual se define en cualquiera de las reivindicaciones 2 a 6 en donde el relleno está presente en una cantidad que oscila entre un 20 y 70% por peso. 8.- Una composición farmacéutica tal cual se define en cualquiera de las reivindicaciones 2 a 7 en donde el aglomerante está presente en una cantidad que oscila entre un 3 y 6% por peso.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US82308306P | 2006-08-21 | 2006-08-21 |
Publications (1)
Publication Number | Publication Date |
---|---|
CO6150163A2 true CO6150163A2 (es) | 2010-04-20 |
Family
ID=39107049
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CO09017334A CO6150163A2 (es) | 2006-08-21 | 2009-02-20 | Composiciones adecuadas para administracion oral que comprende un derivado de triazolo [4,5-d] pirimidina |
Country Status (35)
Country | Link |
---|---|
US (2) | US8425934B2 (es) |
EP (1) | EP2056832B1 (es) |
JP (2) | JP5385139B2 (es) |
KR (1) | KR101539467B1 (es) |
CN (1) | CN101505754A (es) |
AR (1) | AR062451A1 (es) |
AU (2) | AU2007288541B9 (es) |
BR (1) | BRPI0715712B8 (es) |
CA (1) | CA2659328C (es) |
CL (1) | CL2007002421A1 (es) |
CO (1) | CO6150163A2 (es) |
CY (1) | CY1119380T1 (es) |
DK (1) | DK2056832T3 (es) |
ES (1) | ES2625930T3 (es) |
HR (1) | HRP20170694T1 (es) |
HU (1) | HUE031939T2 (es) |
IL (2) | IL196700A (es) |
LT (1) | LT2056832T (es) |
MX (1) | MX340403B (es) |
MY (2) | MY175009A (es) |
NO (1) | NO341787B1 (es) |
NZ (2) | NZ574514A (es) |
PH (1) | PH12013501627A1 (es) |
PL (1) | PL2056832T3 (es) |
PT (1) | PT2056832T (es) |
RS (1) | RS55884B1 (es) |
RU (2) | RU2476223C2 (es) |
SA (1) | SA07280442B1 (es) |
SG (1) | SG177162A1 (es) |
SI (1) | SI2056832T1 (es) |
TW (1) | TWI482772B (es) |
UA (1) | UA99105C2 (es) |
UY (1) | UY30551A1 (es) |
WO (1) | WO2008024045A1 (es) |
ZA (1) | ZA200900991B (es) |
Families Citing this family (38)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TWI229674B (en) | 1998-12-04 | 2005-03-21 | Astra Pharma Prod | Novel triazolo[4,5-d]pyrimidine compounds, pharmaceutical composition containing the same, their process for preparation and uses |
US7056916B2 (en) | 2002-11-15 | 2006-06-06 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Medicaments for the treatment of chronic obstructive pulmonary disease |
US7220742B2 (en) | 2004-05-14 | 2007-05-22 | Boehringer Ingelheim International Gmbh | Enantiomerically pure beta agonists, process for the manufacture thereof and use thereof as medicaments |
BRPI0614410A2 (pt) | 2005-08-15 | 2011-03-29 | Boehringer Ingelheim Int | processo para preparação de betamiméticos |
UY30542A1 (es) * | 2006-08-18 | 2008-03-31 | Boehringer Ingelheim Int | Formulacion de aerosol para la inhalacion de agonistas beta |
TWI482772B (zh) | 2006-08-21 | 2015-05-01 | Astrazeneca Ab | 適合口服且包含三唑并[4,5-d]嘧啶衍生物之組合物 |
WO2011076749A2 (en) | 2009-12-23 | 2011-06-30 | Ratiopharm Gmbh | Solid pharmaceutical dosage form |
CZ2012705A3 (cs) * | 2012-10-16 | 2014-04-23 | Zentiva, K.S. | Pevná orální farmaceutická formulace obsahující ticagrelor |
WO2014170026A1 (en) | 2013-04-18 | 2014-10-23 | Zentiva, K.S. | Stabilized amorphous ticagrelor |
EP2813216A1 (en) | 2013-06-10 | 2014-12-17 | Zentiva, a.s. | Stabilized amorphous ticagrelor |
CA2913326A1 (en) | 2013-05-29 | 2014-12-04 | Ratiopharm Gmbh | Solid pharmaceutical dosage form |
EP2816043A1 (en) | 2013-06-21 | 2014-12-24 | LEK Pharmaceuticals d.d. | Spherical ticagrelor particles |
WO2015001489A1 (en) | 2013-07-01 | 2015-01-08 | Ranbaxy Laboratories Limited | Pharmaceutical compositions of ticagrelor |
CZ2013866A3 (cs) | 2013-11-08 | 2015-05-20 | Zentiva, K.S. | Způsob výroby a nová krystalická forma intermediátu syntézy ticagreloru |
CN104644604A (zh) * | 2013-11-23 | 2015-05-27 | 天津市汉康医药生物技术有限公司 | 替格瑞洛倍半水合物胶囊及其制备方法 |
WO2015110952A1 (en) | 2014-01-21 | 2015-07-30 | Wockhardt Limited | Solid oral pharmaceutical compositions comprising ticagrelor or salt thereof |
CN104940204A (zh) * | 2014-03-27 | 2015-09-30 | 广东东阳光药业有限公司 | 一种替格瑞洛固体制剂及其制备方法 |
CN104098520B (zh) * | 2014-07-23 | 2016-01-20 | 张远强 | 苯基三唑希夫碱类化合物、其制备方法和用途 |
KR20160012706A (ko) | 2014-07-25 | 2016-02-03 | 동아에스티 주식회사 | 서방성 제제 |
CN105832683A (zh) * | 2015-01-15 | 2016-08-10 | 成都国弘医药有限公司 | 一种含有替格瑞洛的片剂 |
WO2016120729A1 (en) * | 2015-01-27 | 2016-08-04 | Astrazeneca Ab | Method of treating or prevention of atherothrombotic events in patients with history of myocardial infarction |
US11357742B2 (en) | 2015-12-14 | 2022-06-14 | X4 Pharmaceuticals, Inc. | Methods for treating cancer |
EP3389634B1 (en) | 2015-12-14 | 2021-10-06 | X4 Pharmaceuticals, Inc. | Methods for treating cancer |
JP7055380B2 (ja) | 2015-12-22 | 2022-04-18 | エックス4 ファーマシューティカルズ, インコーポレイテッド | 免疫不全疾患を処置するための方法 |
CN105709230B (zh) * | 2016-03-01 | 2019-05-31 | 北京鑫兰医药科技有限公司 | 一种替格瑞洛药物组合物及其制备方法 |
CA3019394A1 (en) | 2016-04-08 | 2017-10-12 | X4 Pharmaceuticals, Inc. | Methods for treating cancer |
US20170296666A1 (en) | 2016-04-18 | 2017-10-19 | Amneal Pharmaceuticals Company Gmbh | Stable Pharmaceutical Composition Of Amorphous Ticagrelor |
CN107595789B (zh) * | 2016-04-21 | 2021-01-15 | 阿斯利康(瑞典)有限公司 | 口腔崩解片 |
JP7084624B2 (ja) | 2016-06-21 | 2022-06-15 | エックス4 ファーマシューティカルズ, インコーポレイテッド | Cxcr4阻害剤およびその使用 |
EP3808748A1 (en) | 2016-06-21 | 2021-04-21 | X4 Pharmaceuticals, Inc. | Substituted piperidines as cxcr4-inhibitors |
EP3472129A4 (en) | 2016-06-21 | 2019-12-04 | X4 Pharmaceuticals, Inc. | CXCR4 INHIBITORS AND USES THEREOF |
TR201617983A2 (tr) | 2016-12-07 | 2018-06-21 | Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi | Ti̇cagrelorun kati oral farmasöti̇k bi̇leşi̇mleri̇ |
EP3761965A1 (en) | 2018-03-08 | 2021-01-13 | Pharmaceutical Oriented Services Ltd | Ticagrelor-containing tablet formulation |
WO2020021110A1 (en) | 2018-07-27 | 2020-01-30 | Krka, D.D., Novo Mesto | Pharmaceutical composition of ticagrelor |
US10548889B1 (en) | 2018-08-31 | 2020-02-04 | X4 Pharmaceuticals, Inc. | Compositions of CXCR4 inhibitors and methods of preparation and use |
JP2022035920A (ja) | 2020-08-19 | 2022-03-04 | アストラゼネカ・アクチエボラーグ | 併用療法 |
BR102021011533A2 (pt) * | 2021-06-14 | 2022-12-27 | Libbs Farmacêutica Ltda | Composição farmacêutica e uso da composição farmacêutica |
WO2024089196A1 (en) | 2022-10-28 | 2024-05-02 | Astrazeneca Ab | Recombinant apyrase protein for use in the treatment of an ischemic event at a dose of 40-240 mg |
Family Cites Families (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TWI229674B (en) | 1998-12-04 | 2005-03-21 | Astra Pharma Prod | Novel triazolo[4,5-d]pyrimidine compounds, pharmaceutical composition containing the same, their process for preparation and uses |
SE9904129D0 (sv) | 1999-11-15 | 1999-11-15 | Astra Pharma Prod | Novel compounds |
GB0013407D0 (en) * | 2000-06-02 | 2000-07-26 | Astrazeneca Ab | Forms of a chemical compound |
WO2003053416A1 (en) * | 2001-12-21 | 2003-07-03 | Pfizer Products Inc. | Directly compressible formulations of azithromycin |
MXPA04007937A (es) | 2002-02-15 | 2004-11-26 | Biogal Gyogyszergyar | Composicion en polvo que comprende zaleplon de distribucion de tamano de particula definida y productos farmaceuticos hechos a partir de los mismos. |
US20040001885A1 (en) * | 2002-06-27 | 2004-01-01 | Unchalee Kositprapa | Rapidly disintegrating antihistamine formulation |
HN2003000272A (es) * | 2002-09-10 | 2008-07-29 | Pharmacia Italia Spa | Formulaciones que comprenden un compuesto de indolinona |
US20060039968A1 (en) | 2002-10-08 | 2006-02-23 | Ramalingam Manikandan | Gabapentin tablets and method for their preparation |
US20060189565A1 (en) * | 2002-10-22 | 2006-08-24 | Mathur Rajeev S | Pharmaceutical compositions of ganciclovir |
SE0203778D0 (sv) * | 2002-12-09 | 2002-12-09 | Astrazeneca Ab | A new oral immediated release dosage form |
JP2005538038A (ja) * | 2003-02-19 | 2005-12-15 | テバ ジョジセルジャール レースベニュタールシャシャーグ | 規定された粒子サイズの分布を持つザレプロンを含む粉末組成物、及びそれから作られた医薬製品 |
DE10319450A1 (de) | 2003-04-30 | 2004-11-18 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Pharmazeutische Formulierung des Telmisartan Natriumsalzes |
JP2005162696A (ja) * | 2003-12-04 | 2005-06-23 | Nichiko Pharmaceutical Co Ltd | 溶出性に優れたセフジトレンピボキシル製剤 |
JP2007537184A (ja) | 2004-05-13 | 2007-12-20 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 抗血小板剤に対する耐性を治療するためのジピリダモールの使用 |
WO2006072878A1 (en) | 2005-01-07 | 2006-07-13 | Ranbaxy Laboratories Limited | Oral dosage forms of sertraline having controlled particle size and processes for their preparation |
MX2007009196A (es) * | 2005-01-31 | 2009-02-25 | Optimer Pharmaceuticals Inc | Compuestos macrocilicos de 18 miembros y analogos de los mismos. |
TWI482772B (zh) | 2006-08-21 | 2015-05-01 | Astrazeneca Ab | 適合口服且包含三唑并[4,5-d]嘧啶衍生物之組合物 |
-
2007
- 2007-08-10 TW TW096129721A patent/TWI482772B/zh active
- 2007-08-15 AR ARP070103619A patent/AR062451A1/es not_active Application Discontinuation
- 2007-08-15 SA SA07280442A patent/SA07280442B1/ar unknown
- 2007-08-20 LT LTEP07794121.9T patent/LT2056832T/lt unknown
- 2007-08-20 SG SG2011088689A patent/SG177162A1/en unknown
- 2007-08-20 RU RU2009104330/15A patent/RU2476223C2/ru active
- 2007-08-20 CL CL200702421A patent/CL2007002421A1/es unknown
- 2007-08-20 AU AU2007288541A patent/AU2007288541B9/en active Active
- 2007-08-20 PT PT77941219T patent/PT2056832T/pt unknown
- 2007-08-20 MX MX2009001853A patent/MX340403B/es active IP Right Grant
- 2007-08-20 BR BRPI0715712A patent/BRPI0715712B8/pt active IP Right Grant
- 2007-08-20 ES ES07794121.9T patent/ES2625930T3/es active Active
- 2007-08-20 RS RS20170463A patent/RS55884B1/sr unknown
- 2007-08-20 HU HUE07794121A patent/HUE031939T2/en unknown
- 2007-08-20 KR KR1020097004259A patent/KR101539467B1/ko active IP Right Review Request
- 2007-08-20 DK DK07794121.9T patent/DK2056832T3/en active
- 2007-08-20 CN CNA2007800311371A patent/CN101505754A/zh active Pending
- 2007-08-20 NZ NZ574514A patent/NZ574514A/en unknown
- 2007-08-20 WO PCT/SE2007/000736 patent/WO2008024045A1/en active Application Filing
- 2007-08-20 UY UY30551A patent/UY30551A1/es not_active Application Discontinuation
- 2007-08-20 EP EP07794121.9A patent/EP2056832B1/en not_active Revoked
- 2007-08-20 UA UAA200900509A patent/UA99105C2/ru unknown
- 2007-08-20 MY MYPI2012003213A patent/MY175009A/en unknown
- 2007-08-20 MY MYPI20090666A patent/MY147966A/en unknown
- 2007-08-20 JP JP2009525520A patent/JP5385139B2/ja active Active
- 2007-08-20 CA CA2659328A patent/CA2659328C/en not_active Expired - Fee Related
- 2007-08-20 SI SI200731923A patent/SI2056832T1/sl unknown
- 2007-08-20 PL PL07794121T patent/PL2056832T3/pl unknown
- 2007-08-20 NZ NZ596700A patent/NZ596700A/xx unknown
- 2007-08-20 US US11/841,030 patent/US8425934B2/en active Active
-
2009
- 2009-01-25 IL IL196700A patent/IL196700A/en active IP Right Grant
- 2009-01-28 NO NO20090425A patent/NO341787B1/no unknown
- 2009-02-11 ZA ZA2009/00991A patent/ZA200900991B/en unknown
- 2009-02-20 CO CO09017334A patent/CO6150163A2/es unknown
-
2011
- 2011-08-04 AU AU2011205164A patent/AU2011205164B2/en active Active
-
2012
- 2012-11-28 RU RU2012153069/15A patent/RU2012153069A/ru not_active Application Discontinuation
- 2012-12-21 US US13/724,624 patent/US20130131087A1/en not_active Abandoned
-
2013
- 2013-08-02 PH PH12013501627A patent/PH12013501627A1/en unknown
- 2013-10-02 JP JP2013207138A patent/JP2014040448A/ja active Pending
- 2013-10-29 IL IL229130A patent/IL229130A0/en unknown
-
2017
- 2017-05-10 HR HRP20170694TT patent/HRP20170694T1/hr unknown
- 2017-05-22 CY CY20171100531T patent/CY1119380T1/el unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CO6150163A2 (es) | Composiciones adecuadas para administracion oral que comprende un derivado de triazolo [4,5-d] pirimidina | |
DK200001170A (da) | Farmaceutiske sammensætninger | |
EA200901277A1 (ru) | Фармацевтические составы, содержащие пропиленгликольгидрат дапаглифлозина | |
PE20090964A1 (es) | Derivados de pirrolo[2,3-d]pirimidina como inhibidores de proteina quinasa b | |
PE20100252A1 (es) | Nuevas formulaciones farmaceuticas solidas que comprenden dimaleato de 4-[(3-cloro-4-fluorofenil) amino]-6-{[4-(n,n-dimetilamino)-1-oxo-2-buten-1-il] amino}-7-((s)-tetrahidrofuran-3-iloxi)-quinazolina | |
RU2002103603A (ru) | Фармацевтические композиции, содержащие ингибитор hmg редуктазы | |
RS53570B1 (en) | DPP IV INHIBITOR FORMULATIONS | |
ECSP088120A (es) | Derivados de piridazinona como agonistas del receptorde la hormona tiroidea | |
ECSP088511A (es) | Agonistas del receptor del neuropeptido-2 | |
RU2016122609A (ru) | Составы соединений азаиндола | |
ECSP088973A (es) | Derivados de imidazol pirimidina para el tratamiento de enfermedades relacionadas con la glicógeno sintasa quinasa (gsk3) | |
PE20080376A1 (es) | Formulaciones de comprimidos de liberacion inmediata de un antagonista del receptor de trombina derivado de fluorofenilpiridina | |
AR055015A1 (es) | Derivados fusionados de pirazol composicion farmaceutica y uso del compuesto para fabricar medicamentos. | |
MA29278B1 (fr) | Composition pharmaceutique comprenant un derive de l'indolylmaleimide | |
ECSP11011151A (es) | Compuestos purina | |
CL2009000241A1 (es) | Compuestos derivados de 5-(2-morfolin-4-il-7h-pirrolo[2,3-d]pirimidin-4-il)pirimidin-2-ilamina; proceso de preparacion; composicion farmaceutica; y uso de los compuestos para tratar o prevenir una enfermedad proliferativa tal como el cancer. | |
MXPA04002338A (es) | Derivados de carbazol y su uso como antagonistas receptores del npy5. | |
NO20070681L (no) | 2, 4, 6-Trisubstituterte pyrimidiner som fosfotidylinositol-(PI)-3-kinaseinhibitorer og disses anvendelse i behandling av kreft | |
GT200700103A (es) | Compuestos biciclocarboxiamida sustituidos | |
NZ704171A (en) | Difluorolactam compositions for ep4-mediated osteo related diseases and conditions | |
UY30847A1 (es) | Uso de derivados de mononitrato de dianhidrohexita como agentes para el tratamiento de trastornos intestinales | |
AR071721A1 (es) | Derivados de piridil-prolinamida, composiciones farmaceuticas que los contienen y su uso para el tratamiento de ansiedad, depresion y trastornos del sueno. | |
PE20120990A1 (es) | Formulaciones de alisquireno e hidroclorotiazida | |
ATE527991T1 (de) | Pharmazeutische zusammensetzungen von pramipexol | |
WO2005118558A3 (de) | Pyrimidinverbindungen und ihre verwendung |